Biohaven Pharmaceutical Holding

BHVN

Held by 7 specialist biotech funds

High Convergence

7 funds opened new positions. Short interest: 21.7% of float.

BiotechnologyCEO: Vladimir CoricIPO: 2022Website ↗

Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.

Biohaven Pharmaceutical Holding

Signal Score

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Conferences

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research